Hims & Hers Health (HIMS) Preferred Stock Liabilities (2019 - 2020)
Hims & Hers Health (HIMS) posted Preferred Stock Liabilities of $250.0 million for Q4 2020, up 9.57% sequentially from $228.1 million in Q2 2020, and up 5454.71% YoY from $4.5 million in Q1 2020.
Hims & Hers Health (HIMS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Hims & Hers Health has reported Preferred Stock Liabilities for 2 years, with the latest figure at $250.0 million in Q4 2020.
- Quarterly Preferred Stock Liabilities rose 5454.71% year-over-year to $250.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $250.0 million (up 5454.71% YoY) and the FY2020 annual result came in at $250.0 million, up 5454.71% from the prior year.
- Preferred Stock Liabilities rose to $250.0 million in Q4 2020 per HIMS's latest filing, from $228.1 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $250.0 million in Q4 2020 and troughed at $4.5 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Hims & Hers Health | 7.49 Bn | 6.65 Bn | 480.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 249.96 Mn |
| Jun 30, 2020 | 228.13 Mn |
| Mar 31, 2020 | 218.25 Mn |
| Dec 31, 2019 | 4.50 Mn |